0
0
March 1, 2026
AMSTERDAM — In a landmark move for respiratory medicine, the European Medicines Agency (EMA) recommended marketing authorization on February 27, 2026, for mCombriax, the world’s first combined mRNA vaccine targeting both COVID-19 and seasonal influenza. Developed by Moderna Biotech Spain S.L., the single-dose shot is specifically indicated for adults aged 50 and older. This regulatory milestone aims to streamline seasonal immunization campaigns and reduce the dual healthcare burden of two viruses that continue to strain global medical systems every winter.
Two Targets, One Technology
The mCombriax vaccine represents an evolution in messenger RNA (mRNA) technology. Rather than receiving two separate injections—one for COVID-19 and another for the flu—eligible adults can now gain protection against both through a single intramuscular jab.
The vaccine functions by instructing the body’s cells to produce specific proteins found in:
-
SARS-CoV-2: The virus responsible for COVID-19 (targeted strains align with the most recent EMA 2023/2024 recommendations).
-
Influenza: Four key seasonal strains, including A-H1N1, A-H3N2, and B/Victoria, following World Health Organization (WHO) guidelines.
By using mRNA to “code” for these proteins, the vaccine prepares the immune system to recognize and fight the actual viruses if the person is exposed later. Because influenza and COVID-19 strains mutate rapidly, the vaccine’s composition is designed to be updated annually, mirroring the existing process for seasonal flu shots.
The Evidence: Stronger Together?
The EMA’s Committee for Medicinal Products for Human Use (CHMP) based its positive opinion on a robust Phase 3 clinical trial involving approximately 8,000 participants aged 50 and older.
The trial’s primary goal was to prove “non-inferiority”—meaning the combo shot worked at least as well as the individual vaccines given separately. The results exceeded that benchmark:
-
Antibody Levels: Participants receiving mCombriax produced antibody levels against both COVID-19 and flu that were statistically comparable or, in some cases, superior to those produced by co-administered separate shots (such as Spikevax and Fluzone HD).
-
Specific Strains: In earlier data for the precursor (mRNA-1083), immune responses against H1N1 influenza were significantly higher, with a geometric mean ratio of 1.414 in the 50–64 age bracket compared to standard vaccines.
-
Omicron Protection: The vaccine showed a robust response against the SARS-CoV-2 Omicron XBB.1.5 variant, which remains a key lineage of concern for public health officials.
Safety and Side Effects: What to Expect
As with any vaccine that triggers an immune response, mCombriax does come with a range of “reactogenicity”—the physical signs that the body is building protection.
According to EMA data, more than 1 in 10 recipients experienced:
-
Pain at the injection site
-
Fatigue and headache
-
Muscle and joint pain
-
Chills or low-grade fever
-
Swollen lymph nodes
Most reactions were categorized as mild to moderate, typically appearing within two days of the injection and resolving within three days. Crucially, no new or unexpected safety signals were identified in the combination format compared to the well-documented profiles of standalone mRNA vaccines.
Easing the Public Health Burden
The timing of this authorization is critical. Since the start of the pandemic, Europe has reported over 281 million COVID-19 cases. Meanwhile, seasonal influenza causes up to 50 million symptomatic cases annually across the European Economic Area (EEA).
“This combined vaccine represents a practical advance, reducing the vaccination burden for at-risk populations while leveraging proven mRNA efficacy,” says Dr. Eleanor Torres, an infectious disease specialist at Johns Hopkins Bloomberg School of Public Health, who was not involved in the Moderna trials.
Public health experts hope the “one-and-done” approach will combat “vaccine fatigue.” Data suggests that when patients are required to schedule multiple appointments or receive multiple injections, compliance rates drop. A single shot could significantly boost uptake during the high-stakes fall and winter respiratory seasons.
Balanced Perspective: Limitations and Monitoring
While the medical community is largely optimistic, some experts urge cautious observation. Professor Lars Rönnblom, an immunologist at Uppsala University, noted that while the trial data is “compelling,” real-world effectiveness against rapidly evolving strains will be the ultimate test.
Current limitations of the mCombriax rollout include:
-
Age Restriction: There is currently no data for individuals under 50, meaning younger high-risk groups will still require separate shots for now.
-
Immunogenicity vs. Efficacy: The trials measured antibody levels (immunogenicity) rather than tracking a “real-world” reduction in hospitalizations over several years.
-
Long-term Durability: It is not yet clear how long the dual protection lasts compared to traditional protein-based flu vaccines.
The Path Forward
The EMA’s recommendation now moves to the European Commission for final legally binding approval, which is expected shortly. Moderna anticipates the vaccine will be available in select European markets for the 2026-2027 season.
For the average adult over 50, this news signals a future of simpler healthcare. Instead of navigating two different appointments for two different viruses, the “fall booster” may soon become a singular, streamlined event.
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References
